Effect of a Yoghurt Containing Four Probiotic Lactobacillus Strains on Bacterial Vaginosis
Double-blind, Randomized, Controlled Trial to Evaluate the Effect of a Yoghurt Containing Four Probiotic Lactobacillus Strains (L. Crispatus, L. Gasseri, L. Rhamnosus, L. Jensenii) on Bacterial Vaginosis (BV) in Adult Women
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Germany, 24118
- CRC Clinical Research Center Kiel
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
To be enrolled, the following criteria have to be fulfilled:
- Woman aged ≥ 18 years with stable menstrual cycle or postmenopausal women
- Newly diagnosed bacterial vaginosis based on Amsel criteria
- Complies with a standard oral antibiotic treatment with Metronidazol for 7 days, 2 x 500mg/day)
- Willing to consume for 4 weeks the study product two times daily
- Willingness to abstain from food and supplements containing probiotics, prebiotics and other fermented products as well as dietary supplements
- Not in menses at the time of the first examination at the gynaecologist (G1)
- Written informed consent
Exclusion Criteria:
- Subjects currently enrolled in another clinical study.
- Subjects having finished another clinical study within the last 4 weeks before inclusion.
- Infection caused by Chlamydia trachomatis
- Infection caused by Neisseria gonorrhoea
- Infection caused by Trichomonas vaginalis
- Infection caused by Candida albicans or other mycosis
- Leucocytes present in the vaginal smear
- PAP-testing ≥ 3 (anamnestically)
- Vulvovaginal inflammation as macroscopically identified by the gynaecologist
- Dyspareunia
- Pregnancy and breastfeeding
- Chemically based contraceptives (e.g. suppositories, salves, foam, gel)
- Irregular cycles (e.g. polymenorrhoea, metrorrhagia)
- Dysuria
- Infection of the urinary tract
- Chronic or sporadic abdominal pain with exception of dysmenorrhoea
- Any ano-rectal infection, disease, surgery in the medical history or current
- Anus praeter
- Hypersensitivity, allergy or idiosyncratic reaction to metronidazole or any similar active substances.
- Hypersensitivity, allergy or idiosyncratic reaction to any component of the yoghurt (e.g. lactose intolerance, allergy against milk protein)
- Any disease or condition which might compromise significantly the hematopoietic, renal, endocrine, pulmonary, hepatic, gastrointestinal, cardiovascular, immunological, central nervous, dermatological or any other body system with the exception of the conditions defined by the inclusion criteria.
- History of hepatitis B and C
- History of HIV infection
- Regular medical treatment including OTC, which may have impact on the study aims (e.g. probiotics, antibiotic drugs, laxatives etc.)
- Major cognitive or psychiatric disorders
- Subjects who are scheduled to undergo hospitalization during the study period
- Eating disorders (e.g. anorexia, bulimia) or special diets (e.g. vegan, vegetarian)
- Present drug abuse or alcoholism, reformed alcoholic
- Legal incapacity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: probiotic yoghurt & Arilin
probiotic yoghurt, 2 units (125 g), containing living strains of L.crispatus, L.gasseri, L.rhamnosus, L.jensenii, each in a concentration of 1 x 107 CFU/ml product for 4 weeks Two yoghurts are consumed every day for 28 days.
2 tablets Metronidazol 500mg daily for 7 days
|
verum is a liquid probiotic yoghurt containing all four probiotics as described in the arm description.
Study participants consume daily two bottles (125g) during an intervention period of four weeks.
Other Names:
2 tablets Arilin 500mg for 7 days
Other Names:
|
|
Placebo Comparator: chemically acidified milk & Arilin
chemically (H3PO4) acidified milk (125g) without bacterial strains.
Two products are consumed every day for 28 days.
2 tablets Metronidazol 500mg daily for 7 days
|
2 tablets Arilin 500mg for 7 days
Other Names:
Placebo is chemically acidified milk without bacterial strains.
Study participants consume daily two bottles (125g) during an intervention period of four weeks (randomly assigned).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of BV-free woman
Time Frame: 4 weeks
|
The rate of BV-free women at the end of the yoghurt consumption period (day 28) as assessed by Nugent score
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Alteration (G2 - G1) of Nugent Score
Time Frame: 4 weeks
|
4 weeks
|
|
Alteration (G2 - G1) of symptom score based on Amsel criteria (Yes=1; No=0) and 3 (Yes=1; No=0) resulting in a score ranging from 0 to 2
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Christiane Laue, Dr. med., CRC Clinical Research Center Kiel
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DF-WCT-2014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.